Cue Biopharma Stock Soars Over 40% on Positive Hives Drug Trial Data

Cue Biopharma (NASDAQ: CUE) shares surged in pre-market trading after the company announced positive topline results from a Phase 2 study of its experimental drug, CUE-221, for a chronic skin condition. The clinical-stage biotechnology firm reported that the trial met its primary and key secondary endpoints with high statistical significance, fueling investor optimism about the drug's prospects.

Key Trial Results

The rally was triggered by data from a Phase 2 trial of CUE-221, an anti-IgE monoclonal antibody. The study, conducted in China by Genesis Life Sciences, evaluated the drug in 145 patients with moderate to severe chronic spontaneous urticaria, a condition characterized by persistent and debilitating hives.

According to the company's disclosure, the trial successfully met its goals and CUE-221 demonstrated a favorable safety profile. The study enrolled patients whose symptoms were inadequately controlled by standard antihistamine therapy, a difficult-to-treat population.

Potential Advantage Over Market Leader

A key driver for the market's forceful reaction is data suggesting CUE-221 has a "clinically distinct efficacy profile" compared to omalizumab (XOLAIR®), the current multi-billion dollar standard of care for the condition. This potential for a superior, mechanism-based advantage points to significant commercial opportunity.

Ad

The positive results position Cue Biopharma to potentially advance CUE-221 into a pivotal Phase 2b/3 registration-enabling study, a critical step toward regulatory approval. The company scheduled a conference call for 8:00 a.m. EDT to discuss the findings and path forward.

Market Context and Analyst Confidence

The stock's move was also supported by other factors. B. Riley Securities had initiated coverage on Cue Biopharma with a Buy rating just days earlier, signaling growing institutional confidence. Furthermore, a constructive broader market provided a supportive backdrop for clinical-stage biotechnology names.

In pre-open trading, the stock surged 41.6%, pushing it well above its prior 52-week high and reflecting a significant re-rating of the company's clinical and commercial outlook by investors.